http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0355859-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_359b45ab51dbd97bd513b984a50c5ef0 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J71-0031 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-38 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J71-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F3-00 |
| filingDate | 1986-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1994-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1077ddd1dad8c58f688cfe200e3ac396 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce9e5bbf34b1148498dfd74e2163fe0d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c194db46a2a015bf7d9625c6d26f27a3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58c3c70c8c81faf2b6e678a79b595ec5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2255264c6502da9474a4198dd94d48e2 |
| publicationDate | 1994-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0355859-B1 |
| titleOfInvention | Process for the preparation of intermediates for 11-beta,16-alpha,17-alpha,21-tetrahydroxypregna-3,20-dione 16-alpha,17-alpha-acetals and 21-esters thereof |
| abstract | The invention refers to compounds having anti- inflammetory activity characterized by the formulaor a stereoisomeric component thereof, in which formula the 1,2-position is saturated or is a double bandX, is selected from hydrogen, fluorine, chlorine and bromineX<sub>2</sub> is selected from hydrogen, fluorine, chlorine and bromineR<sub>1</sub> is selected from hydrogen or a straight or branched hydrocarbon chain having 1-4 carbon atomsR<sub>2</sub> is selected from hydrogen or straight and branched hydrocarbon chains having 1-10 carbon atoms andR<sub>3</sub> is selected fromY is O or SR<sub>4</sub> is selected from hydrogen, straight or branched hydrocarbon chains having 1-10 carbon atoms or from phenylR<sub>5</sub> is selected from hydrogen or methyl andR<sub>6</sub> is selected from hydrogen, straight or branched, saturated or unsaturated hydrocarbon chains having 1-10 carbon atoms, an alkyl group substituted by at least one halogen atom, a heterocyclic ring system containing 3-10 atoms in the ring system, -(CH<sub>2</sub>)<sub>m</sub> CH(CH<sub>2</sub>)<sub>n</sub> (m=0,1,2; n=2,3,4,5,6), phenyl or benzyl groups which are unsubstituted or substituted by one or more alkyl, nitro, carboxy, alkoxy, halogen, cyano, carbalkoxy or trifluoromethyl group(s), provided that when R<sub>2</sub> is hydrogen R<sub>1</sub> is methyl.The invention also refers to a process and intermediates for the preparation of these compounds, a pharmaceutical preparation containing one of the compounds and a method for the treatment of inflammatory conditions. |
| priorityDate | 1985-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 187.